The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Severe hypertension (systolic blood pressure (BP) ⩾160 mm Hg) resistant to treatment with multiple antihypertensive medications, poses a serious challenge to therapeutic treatment. Catheter-based ...

Medtronic (MDT) shares reached a session high on Friday amid hopes of expanded reimbursement for renal denervation, a hypertension therapy used in the company’s Symplicity Spyral Renal Denervation ...

Hypertension has a considerable worldwide burden and is a major risk factor for cardiovascular disease. Despite the use of lifestyle measures and medical therapy, a large proportion of patients remain ...

CMS Grants Transitional Pass-Through (TPT) Payment for Recor's Paradise Ultrasound Renal Denervation System The Paradise Ultrasound Renal Denervation (uRDN) system becomes the first and only ...

Experts share practical insights on overcoming referral, reimbursement, and workflow barriers as RDN becomes part of routine ...

BOSTON -- Endovascular renal denervation (RDN) continued to lower blood pressure (BP) in different populations regardless of the specific technology used, according to two late-breaking trial ...

The U.S. CMS has confirmed that it will cover renal denervation as a treatment for hypertension in a final coverage memo that largely mirrors the July 2025 draft. One key difference, however, is that ...

Medtronic plc (NYSE:MDT) is one of the top stock picks in Ken Griffin’s portfolio. On August 25, analysts at TD Cowen reiterated a ‘Buy’ rating on the stock and a $106 price target. The bullish stance ...